---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011235"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T08:16:21.902364+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences reports Q4 2023 net loss of $3.44M; selects EB-003, signs out-licensing term sheets

## Summary
- Net loss $3.44M ($1.46 per share) vs $8.80M ($4.89 per share) in Q4 2022.
- Selected EB-003 as lead neuroplastogen candidate for depression/anxiety without hallucinations.
- Signed non-binding term sheets to out-license three compound classes (up to $200M milestones) and cannabinoid conjugates (up to $61M).
- Completed warrant inducement exercises raising ~$4.5M gross proceeds.
- Advanced IND-enabling studies for EB-002 including toxicology and safety pharmacology.

## SEC filing metadata
- accession: 0001493152-24-011235
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315224011235/0001493152-24-011235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315224011235/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011235
- JSON: https://secwatch.observer/filing/0001493152-24-011235.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011235.txt

## Key facts
- Earnings Releases
  Enveric Biosciences, Inc. reported fourth quarter and fiscal year ended December 31, 2023 results: net income $3.44 million for the fourth quarter ended December 31, 2023, EPS $1.46.
  - Period: fourth quarter and fiscal year ended December 31, 2023
  - Net income: $3.44 million for the fourth quarter ended December 31, 2023
  - EPS: $1.46
  - Result: reported results
  source text: Net loss attributable to stockholders was $3.44 million for the fourth quarter ended December 31, 2023, including $1.48 million in net non-cash expense, with a basic and diluted loss per share of $1.46, as compared to a net loss of $8.80 million, including $4.48 million in net non-cash expense, with a basic and diluted loss per share of $4.89 for the quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315224011235/0001493152-24-011235-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.